THAOS-The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

Current Medical Research and Opinion

Volumn 29, Issue 1, 2013, Pages 63-76

  Coelho, Teresa ^a   Maurer, Mathew S ^b   Suhr, Ole B ^c  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b NewYork Presbyterian Hospital   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Amyloidosis; Familial amyloidotic polyneuropathy; Polyneuropathy; Quality of life; Senile systemic amyloidosis; THAOS; Transthyretin

Indexed keywords

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM EXAMINATION; FEMALE; GENE MUTATION; GENETIC DISORDER; HEALTH SURVEY; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; POLYNEUROPATHY; QUALITY OF LIFE; TRANSTHYRETIN AMYLOIDOSIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; AMYLOID NEUROPATHIES, FAMILIAL; DATA COLLECTION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREALBUMIN; QUALITY OF LIFE;

EID: 84871383407     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.754348     Document Type: Article

References (39)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909
2. Zeldenrust S. ATTR: diagnosis, prognosis and treatment. In: Gertz M, Rajkumar S, eds. Amyloidosis: Diagnosis and Treatment. New York, NY: Humana Press, Springer Science, Business Media LLC; 2010:191-204
3. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30
4. Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299:713-16
5. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62
6. Pitkänen P, Westermark P, Cornwell III GG. Senile systemic amyloidosis. Am J Pathol 1984;117:391-9
7. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543-69
8. Herrick MK, DeBruyne K, Horoupian DS, et al. Massive leptomeningeal amy-loidosis associated with a Val30Met transthyretin gene. Neurology 1996;47:988-92
9. Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003; 60:1625-30
10. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23
11. Hornsten R, Pennlert J, Wiklund U, et al. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010;17:63-8
12. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84
13. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyr-etin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73
14. Buxbaum J, Alexander A, Koziol J, et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 2010;159:864-70
15. Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardio-graphic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J 1998; 19:782-9
16. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53
17. Ranlov I, Alves IL, Ranlov PJ, et al. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med 1992;93:3-8
18. Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloi-dotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-21
19. Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-4
20. Coutinho P, Martins da Silva A, Kopes Lima J, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner G, Pinho e Costa P, Folcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica, 1980:88-98
21. Araki S, Kurihara T, Tawara S, et al. Familial amyloidotic polyneuropathy in Japanese. In: Glenner G, Pinho e Costa P, Folcao de Freitas A, eds. Amyloid and Amyloidosis. Portugal: Excerpta Medica, 1980:67-77
22. Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuro-pathy. Intern Med 1993;32:920-2
23. Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic poly-neuropathy. J Intern Med 1994;235:479-85
24. Plante-Bordeneuve V, Said G. Transthyretin related familial amyloid poly-neuropathy. Curr Opin Neurol 2000;13:569-73
25. Mörner S, Hellman U, Suhr OB, et al. Amyloid heart disease mimicking hyper-trophic cardiomyopathy. J Intern Med 2005;258:225-30
26. Engvall C, Henein M, Holmgren A, et al. Can myocardial strain differentiate hypertrophic from infiltrative etiology of a thickened septum? Echocardiography 2011;28:408-15
27. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
28. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7:497-508
29. Vinik EJ, Vinik AI, Paulson JF, et al. Validation of Norfolk QOL-DN as a measure of QOL in patients with transthyretin familial amyloid polyneuropathy. Presented at the 2011 Peripheral Nerve Society Biennial Meeting, Maryland, MD, USA, 2011
30. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49
31. Hattori T, Takei Y, Koyama J, et al. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy. Amyloid 2003;10:229-39
32. Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid poly-neuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-7
33. Suhr OB, Lindqvist P, Olofsson BO, et al. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 2006;13:154-9
34. Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early-vs late-onset form. Arch Neurol 2002; 59:1771-6
35. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand 1976;198 (Suppl 590):1-64
36. Soares M, Buxbaum J, Sirugo G, et al. Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Hum Genet 1999;104:480-5
37. Drugge U, Andersson R, Chizari F, et al. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet 1993;30:388-92
38. Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6
39. Yamamoto K, Ikeda S, Hanyu N, et al. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. J Med Genet 1998;35:23-30